Aeolus Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AOLS research report →
Companywww.aeoluspharma.com
Aeolus Pharmaceuticals, Inc. , a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology.
- CEO
- Christopher Stanley
- IPO
- 1996
- Employees
- 4
- HQ
- Mission Viejo, CA, US
Price Chart
Valuation
- Market Cap
- $15.21K
- P/E
- -0.00
- P/S
- 0.01
- P/B
- 0.00
- EV/EBITDA
- 0.96
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -38.78%
- Op Margin
- -157.66%
- Net Margin
- -171.39%
- ROE
- -302.81%
- ROIC
- -102.44%
Growth & Income
- Revenue
- $2.08M · -33.27%
- Net Income
- $-3,558,000 · -35.39%
- EPS
- $-0.04 · -100.00%
- Op Income
- $-3,273,000
- FCF YoY
- -27.26%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -5.55
- Avg Volume
- 1.03K
Get TickerSpark's AI analysis on AOLS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 28, 16 | McManus John L | other | 25,000 |
| Mar 4, 16 | McManus John L | other | 250,000 |
| Oct 1, 13 | KUMAR AMIT | other | 100,000 |
| Oct 1, 14 | KUMAR AMIT | other | 100,000 |
| Oct 1, 15 | KUMAR AMIT | other | 100,000 |
| Mar 4, 14 | McManus John L | other | 250,000 |
| Mar 4, 15 | McManus John L | other | 250,000 |
| May 8, 13 | Cavalier David | other | 75,000 |
| May 8, 13 | Suzdak Peter David | other | 75,000 |
| May 8, 13 | Lewis Michael E | other | 75,000 |
Our AOLS Coverage
We haven't published any research on AOLS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AOLS Report →